Laurus Labs Limited has informed the Exchange regarding a press release dated January 21, 2022, titled "Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication".
Laurus Labs Limited has informed the Exchange regarding a press release dated January 21, 2022, titled "Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication".